[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 7 sources · 6 days · First seen · Last updated

Upadacitinib clinical trials for alopecia areata

Overview

Clinical trials for the drug upadacitinib, a Janus kinase (JAK) inhibitor originally developed for rheumatoid arthritis, have demonstrated significant success in treating severe alopecia areata.

Phase 3 clinical program results published in JAMA Dermatology indicate that the medication helps prevent the immune system from attacking hair follicles by blocking inflammatory signals. In studies involving nearly 1,400 participants across North America, Europe, and China, up to 23 percent of patients with severe hair loss achieved complete scalp hair regrowth within six months.

Further research led by Harvard University noted that approximately half of the patients receiving the treatment achieved at least 80 percent hair regrowth within six months. Specifically, within the 30 mg dosage group, 46 percent of patients experienced hair regrowth exceeding 90 percent.

Entities

upadacitinib · JAMA Dermatology · Harvard University · AbbVie

Timeline

  1. 7 days ago

    [HEALTH] 3 sources
    Upadacitinib shows effectiveness in treating severe alopecia areata

    Upadacitinib, an arthritis drug, shows high efficacy in treating severe alopecia areata, with some clinical trial participants regaining full hair regrowth within 24 weeks.

  2. 12 days ago

    [HEALTH] 4 sources
    Upadacitinib shows significant hair regrowth in severe alopecia areata trials

    Clinical trials for the arthritis drug upadacitinib (Rinvoq) showed that up to 23 percent of severe alopecia areata patients achieved complete scalp hair regrowth within six months.

Sources

chiny24.com · intelligentliving.co · interestingengineering.com · newsbytesapp.com · polityka.co.pl · scinexx.de · tech.wp.pl